CIRM Funded Clinical Trials
Transplantation of CRISPR-CAS9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease
Transplantation of CRISPR-CAS9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients with Severe Sickle Cell Disease
Disease Area:
Investigator:
Institution:
CIRM Grant:
Award Value:
$8,389,407
Trial Sponsor:
University of California, San Francisco
Trial Stage:
Phase 1
Trial Status:
Launching
Targeted Enrollment:
N/A
ClinicalTrials.gov ID:
